Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.82 |
| ▸ | RECQL | P46063 | 1/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.62 |
| ▸ | HPGD | P15428 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.61 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.61 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.61 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | GGT1 | P19440 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valeryl Salycilate SCHEMBL6467137 | 0.90 | KDM4E (1.00) | KDM4EKMT2AMEN1RECQLHSD17B10 | |
| Valeryl Salycilate SCHEMBL31287342 | 0.90 | KDM4E (1.00) | KDM4EKMT2AMEN1RECQLHSD17B10 | |
| Diaspirin SCHEMBL30735506 | 0.89 | KDM4E (0.75) | KDM4EKMT2AMEN1RECQLHSD17B10 | |
| Diaspirin SCHEMBL40799 | 0.89 | KDM4E (0.75) | KDM4EKMT2AMEN1RECQLHSD17B10 | |
| SCHEMBL29406927 | 0.89 | KDM4E (0.91) | KDM4EKMT2AMEN1RECQLHSD17B10 | |
| SCHEMBL503905 | 0.89 | KDM4E (0.91) | KDM4EKMT2AMEN1RECQLHSD17B10 | |
| SCHEMBL1858148 | 0.87 | KDM4E (0.88) | KDM4EKMT2AMEN1RECQLHSD17B10 | |
| SCHEMBL6328818 | 0.87 | KDM4E (0.88) | KDM4EKMT2AMEN1RECQLHSD17B10 | |
| SCHEMBL725982 | 0.87 | KDM4E (0.88) | KDM4EKMT2AMEN1RECQLHSD17B10 | |
| SCHEMBL727072 | 0.87 | KDM4E (0.88) | KDM4EKMT2AMEN1RECQLHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1278517-B1 | METHODS FOR IMPROVING SIZE AND APPEARANCE OF A WOUND | AVOCET POLYMER TECHNOLOGIES IN (US) | 2007-05-30 | — | — | EP | claimed |
| EP-3801496-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | Flagship Pioneering Innovations V, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| CN-104829757-B | A kind of ingredient of solid catalyst of olefin polymerization acid esters compound containing bigcatkin willow and its preparation method and application | 中国科学院化学研究所 | 2018-04-27 | — | — | CN | disclosed |
| US-9351980-B2 | Di-aspirin derivatives | THE UNIVERSITY OF WOLVERHAMPTON (GB) | 2016-05-31 | — | — | US | disclosed |
| US-9351980-B2 | Di-aspirin derivatives | THE UNIVERSITY OF WOLVERHAMPTON (GB) | 2016-05-31 | — | — | US | disclosed |
| US-9328057-B2 | Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases | DOMPE' FARMACEUTICI S.P.A. (IT) | 2016-05-03 | — | — | US | disclosed |
| EP-2576495-A1 | NOVEL DERIVATIVES OF MESALAZINE, PROCESS OF THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES | Sofar SPA (IT) | 2013-04-10 | — | — | EP | disclosed |
| US-20130035317-A1 | Di-Aspirin Derivatives | THE UNIVERISTY OF WOLVERHAMPTON (GB) | 2013-02-07 | — | — | US | disclosed |
| US-20130035317-A1 | Di-Aspirin Derivatives | THE UNIVERISTY OF WOLVERHAMPTON (GB) | 2013-02-07 | — | — | US | disclosed |
| WO-2011148297-A1 | NOVEL DERIVATIVES OF MESALAZINE, PROCESS OF THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES | SOFAR SPA (IT) | 2011-12-01 | — | — | WO | disclosed |
| US-20030220497-A1 | Novel diflunisal esters and related compounds | THE UNIVERSITY OF QUEENSLAND | 2003-11-27 | — | — | US | disclosed |
| US-20030157192-A1 | Low temperature disinfectant/sterilant for medical devices and topical applications | HEALTHPOINT, LTD. | 2003-08-21 | — | — | US | disclosed |
| WO-2003066107-A1 | DISINFECTANT/STERILISANT FOR MEDICAL DEVICES AND TOPICAL APPLICATIONS | HEALTHPOINT, LTD. (US) | 2003-08-14 | — | — | WO | disclosed |
| US-6600064-B2 | Reacting dibenzyl ethers with alkylcarbonyloxybenzoic or alkoxycarbonyloxybenzoic acids in the presence of one or more acids as catalyst | BAYER AKTIENGESELLSCHAFT (DE) | 2003-07-29 | — | — | US | disclosed |
| US-6593365-B1 | Method for treating and/or controlling thrombosis in a mammal, comprising administering to a mammal in need thereof an effective dosage of a compound having the formula: | THE UNIVERSITY OF QUEENSLAND (AU) | 2003-07-15 | — | — | US | disclosed |
| EP-1280757-A2 | NEW GAMMA SELECTIVE RETINOIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-05 | — | — | EP | disclosed |
| US-20020128523-A1 | Process for the preparation of hydroxybenzoic benzyl esters | LANXESS DEUTSCHLAND GMBH (DE) | 2002-09-12 | — | — | US | disclosed |
| EP-1238961-A1 | Process for the preparation of benzyl esters of hydroxybenzoic acids | Bayer Aktiengesellschaft (DE) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001083438-A2 | NEW GAMMA SELECTIVE RETINOIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-08 | — | — | WO | disclosed |
| WO-1998046234-A1 | NOVEL DIFLUNISAL ESTERS AND RELATED COMPOUNDS | THE UNIVERSITY OF QUEENSLAND (AU) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220497-A1 | Novel diflunisal esters and related compounds | HPGDS, ALOX12, ALOX15 | KDM4E 3349/4885KMT2A 4790/4885MEN1 4715/4885 |
| US-20030157192-A1 | Low temperature disinfectant/sterilant for medical devices and topical applications | HAO2, CUTA, ALDH7A1 | KDM4E 2045/4885KMT2A 2852/4885MEN1 3992/4885 |
| US-20130035317-A1 | Di-Aspirin Derivatives | SDHA, DLD, DPYD | KDM4E 2764/4885KMT2A 2755/4885MEN1 3500/4885 |
| US-20020128523-A1 | Process for the preparation of hydroxybenzoic benzyl esters | HAAO, HPD, ALKBH3 | KDM4E 202/4885KMT2A 513/4885MEN1 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.